Bimatoprost drug delivery with fractional laser and microneedling for the management of COVID-19 prone positioning-induced facial atrophy and hypopigmentation
- PMID: 34307814
- PMCID: PMC8280367
- DOI: 10.1016/j.jdcr.2021.07.004
Bimatoprost drug delivery with fractional laser and microneedling for the management of COVID-19 prone positioning-induced facial atrophy and hypopigmentation
Keywords: COVID-19; bimatoprost; facial ulcers; hypopigmented scar; laser therapy; proning; skin of color.
Conflict of interest statement
Dr Rossi is a consultant for Almirall, Merz, Dynamed, Canfield Scientific, Evolus, Biofrontera, QuantiaMD, Lam Therapeutics, Regeneron, and Cutera; Mavig: travel; is an advisory board member for Allergan Inc; is an advisor for Skinfix; L'oreal, travel, Dr Anthony Rossi companies; has received a Ward Memorial Research Grant from the 10.13039/100002602American Society for Laser Medicine and Surgery, a research grant from 10.13039/100003395Skin Cancer Foundation, research/study funding from Regen, research/study funding from LeoPharma, and research/study funding from Biofrontera; is an editorial board member for Lasers in Surgery and Medicine and Cutis Journal; is an assistant editor for Journal of the American Academy of Dermatology; is a board member for American Society for Dermatologic Surgery; and is a committee member and/or chair for American Academy of Dermatology, American Society for Dermatologic Surgery, and American Society for Laser Medicine and Surgery. Author Wilson and Drs Aleisa and Menzer have no conflicts of interest to declare.
Figures


References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources